Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific transaction notification dated January 7, 2021, and filed on January 11, 2021. The document serves as a transaction notification regarding a purchase of company securities by a Principal Director or Manager (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W1053 |
| Transaction Price | $38.0700 per ADS |
| Volume | 194 ADSs |
| Transaction Date | January 7, 2021 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single acquisition of 194 ADSs by Dr. H. Barron within his GSK 401(k) Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a routine disclosure of insider trading activity compliant with Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The purchase was made through a 401(k) Plan account, indicating a routine retirement contribution rather than a discretionary open-market purchase.
- Volume Significance: The volume of 194 shares is nominal and does not indicate a significant change in insider sentiment or holdings.
- Financial Data Absence: Investors should not look to this filing for quarterly or annual financial results; those are found in Form 20-F or earnings releases.